Gregory Robinson, Ph.D., joins the Advisory Board of Odylia Therapeutics, a nonprofit biotech dedicated to bringing treatments for rare disease to patients. He is the Chief Science Officer at Akouos and brings to Odylia extensive biotech experience in gene therapy, ophthalmology, and the rare disease space.
